You just read:

Jazz Pharmaceuticals Announces FDA Acceptance of NDA for Solriamfetol (JZP-110) for Excessive Sleepiness Associated with Narcolepsy or Obstructive Sleep Apnea

News provided by

Jazz Pharmaceuticals plc

02 Mar, 2018, 13:30 GMT